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Abstract  
AIM: The role of behavioural factors and sleep duration and quality is important in the pathogenesis of obesity. The aim 
of our study was to evaluate the effects of behavioural risk factors on melatonin secretion in women. 
SUBJECTS AND METHODS: In total, 120 female patients were enrolled in the study and divided into two groups 
according to the body mass index. Detailed history, anthropometric measurements, urine and blood samples were 
evaluated for each patient. 
RESULTS: Two groups significantly differed in weight, BMI, and waist circumference, and were 94.2 ± 14.9 kg, 33.4 ± 
5.23 kg/m2 and 99.2 ± 12.6 cm for the study group and 56.0 ± 5.2 kg, 20.0 ± 1.8 kg/m2 and 60.1 ± 10.4 cm for the 
control group, respectively, sleep disruptions were detected in 48 patients from study group, with mean score 6.76 ± 
3.6, and only 10 patients were detected in the control group, with mean score 4.42 ± 1.68. Eating disturbances were 
revealed in 66 patients from the study group and 21 patients from the control group. Melatonin levels were 17% higher 
in the study group, compared to control group. 
CONCLUSION: Higher melatonin levels in patients with obesity and concomitant behavioural impairments may be due 
to its protective effect to fight free radicals and to induce vasodilatation. Further studies are needed to confirm our 
finding. 
 
 
 
 
 
Introduction 
 
Obesity is a major medical, social and 
economical health problem of modern century, 
contributing to impairment of quality of life, lost 
productivity, development of serious comorbidities 
and invalidation. Statistically, obesity prevalence is 
three times higher in women, than in men and the 
prognosis is even pessimistic; by 2025, every 
second female with childbearing potential will be 
obese [1]. Increased incidence of obesity among 
females with childbearing potential is especially 
important because it influences not only reproductive 
capacity, including infertility but also causes early 
development of serious chronic diseases such as 
arterial hypertension, ischemic heart disease, 
atherosclerosis and diabetes mellitus [2]. Moreover, 
overweight and obesity have been demonstrated to 
be important risk factors for several types of 
cancers including those that involve the 
reproduction- related tissues [1]. 
Among multiple etiological factors, including, 
genetics, age, sex, profession, health conditions 
(pregnancy, lactation, menopause), endocrine 
disorders, environmental factors and many others [1, 
2], published studies over the last years, have 
provided considerable evidence regarding the 
important role of behavioral factors in development of 
obesity. Behavioral factors, including inadequate 
dietary habits and night eating syndrome, sedentary 
lifestyle and sleep disturbance, are responsible for 
development of obesity “pandemic” [3]. 
Numerous studies have shown the 
correlation between sleep disturbance and 
development of cardio- metabolic disorders [3]. 
According to the data of longitudinal studies, the 
prevalence of insomnia among the obese population 
is 3.9-22.1% [4]. Therefore, many authors 
recommend adding sleep disturbance, and mostly 
obstructive sleep apnea, as one of the components of 
metabolic syndrome [3, 5]. 
Obesity and sleep disturbances are comorbid 
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conditions, with underling neuroendocrine genesis [6]. 
However, the molecular mechanisms that are 
involved in the association between them remain 
unclear. Melatonin is an important regulator of 
circadian rhythm and its action on sleep-wake phase 
has already been proven [7]. Furthermore, melatonin 
has an important positive affect on 
immunomodulation and oncostatin, and it has also 
shown to have antiproliferative and antihypertensive 
effects [4, 8]. 
After entering the circulation, melatonin acts 
as an endocrine factor and a chemical messenger 
of light and darkness. It regulates a variety of 
important central and peripheral actions related to 
circadian rhythms [9]. It also affects the brain, 
immune, gastrointestinal, cardiovascular, renal, bone 
and endocrine functions and acts as an oncostatic 
and anti-aging molecule. Growing scientific evidence 
of melatonin, also suggests that it has some role in 
anorexia nervosa and bulimia [10, 11]. 
Therefore, the aim of our study is to 
evaluate the effects of behavioural risk factors on 
melatonin secretion in women with childbearing 
potential. 
 
 
Subjects and Methods 
 
The study population was derived from a 
database of National Institute of Endocrinology, 
Tbilisi, Georgia, during 2013 -2016 yy. The local ethics 
committee has approved the study. 
The following inclusion criteria used to identify 
the study cohort was: (1) female patients of 
childbearing potential (age 16-35 years); (2) body 
mass index > 25 kg/m
2
; (3) Stable course of 
concomitant disease; (4) Signed informed consent 
before participation in the study. 
Patients, with endocrine disorders, chronic or 
acute liver and kidney disease or cancer and with the 
history of corticosteroid use for three months before 
the informed consent was obtained, were excluded 
from the study. 
In total, 120 female patients were enrolled in 
the study. Eighty female patients of childbearing 
potential with body mass index (BMI) > 25 kg/m
2 
were selected for the study group. Forty females, 
with BMI 19.0-24.9 kg/m
2
, matched by sex and age, 
were selected for the control group. 
Following components were evaluated for 
each patient: detailed history (including demography, 
genetic predisposition, behavioural disorders (sleep, 
eating, physical activity, alcohol and tobacco use) 
and concomitant disorders), anthropometric 
measurements, ultrasonography of abdominal cavity, 
urine and blood samples for analysis. 
Several established measures of disordered 
eating and sleeping were included in the survey. 
Pittsburg Sleep Quality Index was used to 
measure quality and patterns of sleep [12]. Seven 
areas are evaluated with this questionnaire, including 
subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of 
sleeping medications, and daytime dysfunction over 
the last month. A total score of “5” or greater is 
indicative of poor sleep quality. 
Eating habit disorders were evaluated by 
DEBQ (Dutch Eating Behavior Questionnaire) that 
was developed in Netherlands in 1986. The 
questionnaire gives us the opportunity to distinguish 
between restrained, emotional, and external eating 
habits [13]. Emotional eating is defined as eating in 
response to emotional arousal states such as fear 
anger or anxiety, external eating arose in response to 
external food cues such as sight and the smell of food 
and under restraint eating is meant overeating after a 
period of slimming when the cognitive resolve to diet 
is abandoned. For assessment of eating habit, we 
also evaluated the patterns, numbers and 
characteristics of eating. Nighttime eating was 
assessed according the following criteria: ≥ 25% of 
total daily food intake at nighttime and/or two or 
more episodes of nighttime eating per weak and 
morning anorexia for at least three month period [14]. 
Anthropometric data, including height and 
weight, were collected for each patient using Seca 
Medical 763. Waist circumference was measured at 
the midpoint between the lower margin of the least 
palpable rib and the top of the iliac crest, using a 
stretch-resistant tape (Waist circumference and 
waist–hip ratio: report of a WHO expert consultation, 
Geneva, 8–11 December 2008). 
BMI was calculated using WHO classification, 
where BMI is defined as the weight in kilograms 
divided by the square of the height in meters (kg/m
2
). 
Ultrasonography of abdominal cavity was 
performed by Philips Clearview 550. 
Blood samples were drawn after 10 hour 
fasting period. Fasting glucose and lipid profile 
(including total cholesterol, triglycerides, HDL-
cholesterol and LDL-cholesterol) were measured 
using BioSystem A-15 (automatic analyser). 
Melatonin metabolite six sulfatoxymelatonin levels 
were evaluated in morning urine sample and 
assessed by imunoenzyme method (Rayto RT-
2100C), using IBL: melatonin sulphate 6–
sulfatoxymelatonin, ELISA, DRG test system. 
Significant level was set at p < 0.05. Odds 
ratio (OR) was defined for behavioural disorders, with 
95%- confidence interval (CI) and positive and 
negative predictive value was calculated, using table 
(2X2). For comparative analysis of study and control 
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groups () was identified with P critical value < 
0.05. Pearson’s correlation coefficient (r) was 
calculated to determine the relationship between 
study parameters. Statistical analysis was performed 
using Microsoft Excel 2010 and SPSS/v15 software 
packages. 
 
 
Results 
 
Mean age of the total study population was 
29.7 ± 5.01 years. Two groups significantly differed in 
weight, BMI, and waist circumference, and was 94.2 ± 
14.9 kg, 33.4 ± 5.23 kg/m
2 
and 99.2 ± 12.6 cm for the 
study group and 56.0 ± 5.2 kg, 20.0 ± 1.8 kg/m
2 
and 
60.1 ± 10.4 cm for the control group, respectively. 
All patients from the study group had liver 
hepatosis of mild to a moderate degree; while no 
cases of liver hepatosis were seen in any subject from 
the control group. 
The mean duration of obesity in the study 
group was 7.49 ± 7.04 years. Baseline characteristics 
of the study population are given in Fig. 1. 
 
Figure 1: Concomitant somatic disease in study population (%) 
 
The detailed characteristics of behavioural risk 
factors for both groups are presented in Fig. 2. 
 
Figure 2: Differences in behavioural risk factor distribution among 
studied groups (%) 
 
According to Pittsburg Sleep Quality Index, 48 
patients from study group (60%) were detected with 
sleep disruptions, with mean score 6.76 ± 3.6, 
whereas, only ten patients were detected in the 
control group (25%), with mean score 4.42 ± 1.68. 
The sleep disruptions were in correlation with 
According to DEBQ (Dutch Eating Behavior 
Questionnaire), eating disturbances were revealed in 
66 patients (89.2%) from the study group and 21 
patients (67.7%) from the control group. Detailed 
characteristics of eating impairments are given in Fig. 
3. 
 
Figure 3: Distribution of types of eating disorders between studied 
groups (%) 
 
Odds ratio with 95% CI was measured for 
behavioural factors, as potential risk factors for 
obesity. The data on quantitive indicators of 
behavioural risk factors are presented in Table 1. 
Table 1: Quantitative indicators of behavioural risk factors in 
total study population (n=120) 
Behavioral risk factors Study group 
N = 80 
Control group 
N = 40 
OR CI Pv+ Pv– 2 P 
Irrational eating 69 (86.3%) 14 (35.0%) 11.65 4.31-32.38 0.83 0.70 30.48 0.0001 
Impairment of eating 
schedule 
65 (81.3%) 17 (42.3%) 5.86 2.34–14.92 0.79 0.61 16.76 0.0001 
Impairment of eating 
patterns 
66 (82.5%) 21 (52.5%) 4.27 1.69-10.90 0.76 0.58 10.58 0.002 
Sleep disorders 65 (81.3%) 20 (52.0%) 4.33 1.74–10.93 0.76 0.57 11.14 0.001 
Impairment of sleep 
quality 
48 (60%) 10 (25%) 4.50 1.80–1.47 0.83 0.48 11.71 0.001 
Decreased physical 
activity 
61 (76.3%) 21 (52.5%) 2.91 1.20–7.06 0.74 0.5 5.90 0.015 
 
Insulin resistance and disorders in lipid 
profile were seen in 49 and 48 patients from the 
study group (61.3 and 60%, respectively) and were 
not seen in any patient in the control group. 
Interestingly, statistically significant correlation was 
seen between dislipidemia status and obesity duration 
for more than ten years (P = 0.027), excessive intake 
of products rich in fat (P = 0.019), impairment of 
eating schedules (P = 0.045) and sleep disruptions (P 
= 0.010). Melatonin levels were 17% higher in the 
study group, compared to control group (130.6 ± 
124.1 and 107.5 ± 103.9 ng/ml). Because of 
inconsistent melatonin levels in the present study, 
there was seen no correlation of melatonin with any 
study components. 
 
 
Discussion 
 
Statistically, a significant association was 
seen between overweight and obesity with impaired 
behavioural risk factors. The odds ratio was 
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especially high for irrational eating (OR–11.65), 
eating schedule impairments (OR–5.86) and 
disruptions in sleep quality (OR–4.50). Furthermore, 
the prognostic value of positive response was also 
high in above-mentioned impairments and was 83%, 
79% and 83%, respectively. 
The two studied groups significantly differed 
according to the disturbances in eating patterns. The 
external type was the primary eating impairment in 
the control group, while the combination of two or 
three impairment types was seen in the study group, 
indicating the greater effect of overweight and obesity 
on behavioural factors. Our results are in line with the 
majority of publications, were more then half of female 
patients with obesity are prone to have obvious 
impaired eating patterns and the rest have hidden 
disruptions, that are covered by comorbid neuro-
psychological disorders, including depression, 
hypochondria, anxiety, etc. Literature data indicate 
that obese people, among other eating disorder, also 
have impaired external eating behavior, indicating that 
they respond not only on internal (glucose and free 
fatty acid levels, gastric fulness), but also on external 
stimuli (advertisement), while lean individuals respond 
to external stimuli only in case of hunger [15]. The 
current study revealed that people without obesity 
also have the external eating disorders that might be 
explained by the fact, that lean person; do not have 
to control their appetite because of not having a 
weight problem, unlike obese individuals, who 
suppress their appetite, not always realizing it. 
The present study revealed that prevalence of 
the sleep disruptions was 1.5 times higher in the 
study group, compared to the control group and was 
seen in 66 (82.5%) vs. 19 (47.5%) patients, 
respectively (2–10.580, P = 0.002). Most common 
complaints were a reduction of sleep duration, 
frequent awakening during nighttime and somnolence 
during the daytime. Mean duration of sleep was 7.4 ± 
1.3 hour. 
Several studies have reported an 
association between chronic sleep deprivation and 
long-term weight gain. As of today, over 40 studies 
describe either an inverse or U-shaped relationship 
between self-reported sleep disorders and weight 
gain. Severe sleep deprivation has been shown to 
reduce insulin sensitivity via increased cortisol, 
cytokines, and other endocrine and immune 
mechanisms and increase appetite via decreased 
leptin and increased ghrelin levels [16]. 
Our findings are in contrast with some 
publications, were melatonin secretion deficiency is 
considered as the primary reason for sleep 
disruptions [11]. It is important to note, that melatonin 
hypersecretion is often seen in the pathogenesis of 
such disorders, as menopause syndrome, nighttime 
hypertension and hyperplastic processes of uterus 
and ovaries [15]. According to some authors, 
hypermethioninemia, similarly to low serum melatonin 
levels, is associated with neuro-vegetative and 
metabolic disorders and worsens the course of 
primary disease [18]. 
Our results according to melatonin levels were 
inhomogenous in the study groups. Nineteen patients 
in the study group had decreased melatonin levels 
(mean level 32.2 ± 14.1 ng/ml) and sleep deprivations 
expressed by late sleep or night eating syndrome. It is 
well known that night eating syndrome is not a just 
psychological disorder, but has underlying hormonal 
disbalance of decreased melatonin and increased 
cortisol levels [14, 4]. 
Controversial results, concerning the elevated 
melatonin levels in the study group, were seen in the 
majority of patients. Increased melatonin levels were 
associated with eating behaviour disorders (136.6 ± 
132.2 ng/ml), low physical activity level (139.4 ± 
117.5 ng/ml) and sleep deprivation (141.9 ± 133.5 
ng/ml). According to various authors, melatonin 
hypersecretion during metabolic syndrome is induced 
due to increased sympathetic activity on 
suprachiasmatic nuclei. Furthermore, chronic insulin 
resistance studies, melatonin has been shown proven 
antioxidant capacity, expressed by strong free radical 
scavenging properties and vasodilation activity, 
indicating that hypersecretion of this hormone may be 
compensatory, due to protective effect [17]. There 
are some data, where people are divided into 
normal, hypo and hypermelatoninemics. Beside 
similar sleep patterns, people may have significantly 
different melatonin levels in the urine, indicating that 
other mechanisms, then sleep, are involved in the 
metabolism of melatonin. Our results are also in line 
with abovementioned data, confirming the 
multifactorial pathogenesis of melatonin secretion 
and the importance of its quality of action, rather 
than quantity. 
Prevalence of melatonin hypersecretion was 
high in patients with obesity and concomitant 
behavioural impairments, such as eating disorders, 
sleep disruption and reduced physical activity. As 
other hormones, including leptin, ghrelin and cortisol, 
are also involved in the pathogenesis of obesity, it will 
be interesting to evaluate the effect of all these 
hormones on behavioural impairments. More detailed 
evaluation will have practical value and might help to 
develop new ways of diagnosis and treatment of 
obesity. More studies are needed to better 
understanding of this mechanism. 
In conclusion, people with same sleep 
patterns may have decreased normal or elevated 
levels of melatonin that might be due to several 
mechanisms. In present studies, data regarding 
melatonin levels were also inconsistent. Higher 
melatonin levels in patients with obesity and 
concomitant behavioural impairments may be due to 
its protective effect to fight free radicals and to induce 
vasodilatation. Further studies are needed to confirm 
our finding. 
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